Status | Study |
Completed |
Study Name: Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis Condition: Sporadic Inclusion Body Myositis (sIBM) Date: 2014-03-20 Interventions: Drug: BYM338 (Bimagrumab) |
Completed |
Study Name: Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients Condition: Sporadic Inclusion Body Myositis Date: 2013-08-15 Interventions: Drug: BYM338/bimagrumab BYM338 |
Active, not recruiting |
Study Name: Natalizumab in Inclusion Body Myositis (IBM) Condition: Inclusion Body Myositis (IBM) Date: 2013-05-31 Interventions: Drug: Natalizumab Other Name: Tysabri |
Active, not recruiting |
Study Name: Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis Condition: Becker Muscular Dystrophy Sporadic Inclusion Body Myositis Date: 2012-01-23 Interventions: Biological: rAAV1.CMV.huFollistatin344 |
Recruiting |
Study Name: Exercise in Sjogren, Myositis and Takayasu's Arteritis Condition: Primary Sjogren´s Syndrome Myositis Date: 2011-11-29 Interventions: Other: Exercise training "Sjöegren arm": 30 |
Completed |
Study Name: Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis Condition: Sporadic Inclusion Body Myositis Date: 2011-08-12 Interventions: Biological: BYM338 Biological: Placebo |
Completed |
Study Name: Anakinra in Myositis Condition: Polymyositis Dermatomyositis Inclusion Body Date: 2010-07-16 Interventions: Drug: Anakinra |
Recruiting |
Study Name: A Case-control Study to Assess Risk of Coronary Heart Disease in Idiopathic Inflammatory Myopathy Condition: Idiopathic Inflammatory Myopathy Date: 2009-09-03 |
Completed |
Study Name: Lithium in Inclusion Body Myositis (IBM) Condition: Inclusion Body Myositis Date: 2009-06-08 |
Completed |
Study Name: Muscle Strength and Inflammatory Response in Patients With Inclusion Body Myositis Condition: Inclusion Body Myositis Date: 2009-05-11 |